| Schedule of loss per common share |
| | | | | | | | | | | | | For the Three Months Ended June 30, | | For the Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | Net Loss | $ | (1,858) | | $ | (5,056) | | $ | (8,500) | | $ | (9,277) | | | | | | | | | | | | | Basic Weighted-Average Shares | | 41,274,853 | | | 33,853,310 | | | 38,653,838 | | | 33,837,377 | Effect of Dilutive Securities: | | | | | | | | | | | | Dilutive effect of potential common shares issuable (1) | | — | | | — | | | — | | | — | Diluted Weighted-Average Shares | | 41,274,853 | | | 33,853,310 | | | 38,653,838 | | | 33,837,377 | Loss per Common Share | | | | | | | | | | | | Basic | $ | (0.05) | | $ | (0.15) | | $ | (0.22) | | $ | (0.27) | Diluted | $ | (0.05) | | $ | (0.15) | | $ | (0.22) | | $ | (0.27) |
| (1) | For both the three and six months ended June 30, 2026, the Company had approximately 0.1 million of stock options, warrants, outstanding restricted stock units, and convertible debt excluded from the diluted shares calculation as their inclusion would be antidilutive due to a net loss for the respective periods. For both the three and six months ended June 30, 2025, the Company had approximately 1.0 million of stock options and outstanding restricted stock units excluded from the diluted shares calculation as their effect would have been anti-dilutive due to a net loss for the respective periods. |
|